International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 8.27.2020
banner-doctors-analyze.jpg
blog-imwg-2020-virtual.jpg
The 11th Annual IMWG Summit — A Great Success
The IMF hosted the International Myeloma Working Group (IMWG) Summit in virtual fashion on August 25-26. The pandemic may have prevented these top myeloma researchers from meeting in the flesh, but it couldn’t stop their efforts in a search for a pathway to a cure.
2020BlogButton.png
BCAM-banner.jpg
September Is Blood Cancer Awareness Month
With your help, the IMF’s Blood Cancer Awareness Month (BCAM) campaign strives to reach outside of the myeloma community to educate those who are unaware of or unfamiliar with the disease. We encourage you to click the link below and download shareable graphics to post on your social media channels!
2020WatchNowButton.png
IMWG_CHNG_FACON.jpg
The IMF Honors Cancer Researchers Thierry Facon, MD, and Wee Joo Chng, MD
The International Myeloma Foundation is pleased to announce the recipients of the 2020 International Myeloma Working Group (IMWG) Awards. Awarded this year on August 26, 2020, during the 11th Annual Summit, the IMWG Awards each year recognize outstanding multiple myeloma specialists whose work has significantly improved the lives of patients. This year’s award winners are Thierry Facon, MD, the recipient of the 2020 Robert A. Kyle Lifetime Achievement Award, and Wee Joo Chng, MD, the 2020 Brian G.M. Durie Outstanding Achievement Award honoree.
2020LearnMoreButton.png
beth-faiman.jpg
Congratulations to Dr. Beth Faiman of the IMF’s Nurse Leadership Board
On August 1, 2020, Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN, (Cleveland Clinic —Taussig Cancer Center) was appointed the role of Editor-in-Chief of the Journal of the Advanced Practitioner in Oncology (JADPRO). A founding member of the International Myeloma Foundation’s Nurse Leadership Board, Dr. Faiman said, “It is an honor to take on this responsibility to provide relevant and up-to-date information for the advanced practitioner. I intend to continue the journal’s mission to improve the quality of care for patients with cancer through education and addressing critical issues of interest.”
2020LearnMoreButton.png
EuroComm.jpg
The European Commission Approves Belantamab Mafodotin to Treat Relapsed or Refractory Myeloma
On August 26, 2020, the European Commission (EC) “granted conditional marketing authorization for BLENREP (belantamab mafodotin) as a monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.” The approval is based on the 13-month DREAMM-2 data and follows the U.S. FDA approval this August. With the EC’s approval, BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved in Europe.
2020LearnMoreButton.png
hawaii-raffle-inside-house.jpg
And This Too Shall Pass….
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself just minutes from the Hawaiian coastline. Note: Bookings will be in the future based on mutual availability with you and the property owner.
2020LearnMoreButton.png
ONS 2020 Web Banner Final
Attention Oncology Nurses!
Register NOW for a FREE CNE-accredited symposium on best practices and innovations in myeloma care. Four highly experienced nurses will share real-life patient case scenarios. This IMF-hosted virtual symposium takes place on September 8, 2020, at 2 p.m. PT / 5 p.m ET.
2020LearnMoreButton.png
ADD-covid-safety-patients-min.jpg
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

COVID-19 FAQ #22: Have the safety recommendations changed for myeloma patients?
Watch Now
 
Clinical Trials
OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Miracles for Myeloma
Virtual 5K Run/Walk/Bike

Watch a Replay
IMF Patient & Family Webinar

Smile More Auction
Laughs 4 Life

Click here to see all events
 

We Thank Our Sponsors:

Amgen; Bristol-Myers Squibb; Genentech; GSK; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
2020ButtonDonateBurg.png
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
1-800-452-2873
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page